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Abstract 
Objectives 
To report the first clinical experience with a temporary implantable nitinol device (TIND; Medi-
Tate
®
) for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic 
hyperplasia (BPH). 
Patients and Methods 
In all, 32 patients with LUTS were enrolled in this prospective study, which was approved by our 
Institutional Ethics Committee. Inclusion criteria were: age >50 years, International Prostate 
Symptom Score (IPSS) of ≥10, maximum urinary flow rate (Qmax) of ≤12 mL/s, and prostate 
volume of <60 mL. The TIND was implanted within the bladder neck and the prostatic urethra 
under light sedation, using a rigid cystoscope. The device was removed 5 days later in an outpatient 
setting. Demographics, perioperative results, complications (according to the Clavien system), 
functional results and quality of life (QoL) were evaluated. Follow-up assessments were made at 3 
and 6 weeks, and 3, 6 and 12 months postoperatively. The Student's t-test, analysis of variance 
(anova), Kruskall–Wallis test, and simple and multiple linear regression models were used in the 
statistical analyses. 
Results 
The mean patient age was 69.4 years, the mean (standard deviation, sd) prostate volume was 
29.5 (7.4) mL and the Qmax was 7.6 (2.2) mL/s. The median (interquartile range, IQR) IPSS was 
19 (14–23) and QoL score was 3 (3–4). All the implantations were successful, with no 
intraoperative complications recorded. The mean operative time (sd) was 5.8 (2.5) min and the 
median (IQR) postoperative stay was 1 (1–2) day. All but one of the devices (96%) was removed 
5 days at after implantation in an outpatient setting. Four complications (12.5%) were recorded, 
including urinary retention (one, 3.1%), transient incontinence due to device displacement (one, 
3.1%), prostatic abscess (one, 3.1%), and urinary tract infection (one, 3.1%). Multiple regression 
analysis failed to identify any independent prognostic factor for complications. There were 
statistically significant differences in the IPSS, QoL score and Qmax when comparing pre- and 
postoperative results at every time point. After 12 months, the median (IQR) IPSS and QoL score 
were 9 (7–13) and 1 (1–2), respectively, and the mean (sd) Qmax was 12 (4.7) mL/s. The mean 
variations with respect to baseline conditions at the same time points were −45% for the IPSS and 
+67% for Qmax. At 12 months after surgery (last follow-up visit), no patients required medical 
therapy or surgical procedures for BPH. 
Conclusion 
TIND implantation is a feasible and safe minimally invasive option for the treatment of BPH-
related LUTS. The functional results are encouraging and the treatment significantly improved 
patient QoL. Further studies are required to assess durability of TIND results and to optimise the 
indications of such a procedure. 
Introduction 
Moderate-to-severe LUTS resulting from BPH affect ≈30% of men aged >50 years, including 
26 million men in Europe and 8 million in the USA [1]. Medical therapy (α-blockers and 5α-
reductase inhibitors) is often the first therapeutic option for these patients, even if it provides only 
modest symptomatic relief, as assessed by improvements in the IPSS [1, 2]. Due to the incidence of 
side-effects, together with inadequate symptoms relief, >25% of patients on drug therapy 
discontinue treatment; some of these patients opt for surgical intervention [1, 2]. 
TURP remains the ‘gold standard’ in the surgical treatment of BPH, and has documented decreased 
IPSS and increased maximum urinary flow rate (Qmax) by up to 70% and 149%, respectively [3-6]. 
The main disadvantages of TURP include perioperative morbidity and long-term complications, 
such as postoperative bleeding, urinary retention, incontinence, urethral strictures and sexual 
dysfunction (up to 65% of patients if retrograde ejaculation is considered) [6]. The newer, 
extremely attractive laser-based methods of treatment such as holmium laser enucleation of the 
prostate, thulium laser enucleation of the prostate, and photovaporisation of the prostate, are still 
associated with complication rates comparable with those of TURP [7, 8]. 
Considering these findings, there is still a considerable proportion of men who seek more 
significant symptomatic improvement than is offered by medicinal therapy but who are not willing 
to subject themselves to the risks associated with surgery. Thus, different minimally invasive 
procedures have been introduced with the aim of reducing the morbidity of TURP, such as 
transurethral needle ablation (TUNA), transurethral microwave thermotherapy (TUMT), and 
transurethral ethanol ablation of prostate (TEAP). However, their position in the management of 
BPH is still controversial [5, 7]. More recently, a step in this direction was made: some reports 
presented data about a new procedure called prostate urethral lift (PUL) [9, 10]. 
In the present study, we report the first clinical experience with a temporary implantable nitinol 
device (TIND; Medi-Tate
®
; Medi-Tate Ltd., Or Akiva, Israel), a new device developed to provide a 
minimally invasive means of increasing prostatic urethral patency to relieve the symptoms of 
urinary outflow obstruction secondary to BPH. The TIND is crimped and delivered through a 
cystoscope sheath, and then, when placed in the urethra, it is released from the cystoscope sheath to 
assume its expanded configuration, thereby reshaping the urethra and the bladder neck. The purpose 
of the present study was to determine the feasibility and safety of the TIND procedure in patients 
with LUTS due to BPH. 
Patients and Methods 
Study Design 
In this single-arm, prospective study, we evaluated the feasibility and the safety of TIND 
implantation in patients presenting with LUTS secondary to BPH. After the approval of the Local 
Institutional Ethic Committee, the study was conducted at the Division of Urology, San Luigi 
Gonzaga Hospital, University of Turin, Orbassano (Turin), Italy and the enrolment phase lasted 
from May 2010 to July 2013. All patients were accurately informed about the procedure and signed 
a detailed consent form. 
Inclusion Criteria 
Age >50 years, IPSS of ≥10, Qmax of ≤12 mL/s, prostate volume assessed by TRUS of <60 mL. 
Exclusion Criteria 
Previous prostate surgery, prostate cancer, urethral stricture, bladder stones, obstructing median 
lobe. Patients were also excluded if they had a history of significant medical co-morbidity, 
haemostatic disorder or suspected neurological conditions that could potentially affect voiding 
function. 
TIND and Surgical Equipment 
The TIND is comprised of elongated struts and an anchoring leaflet all made of nitinol, a 
biocompatible super elastic shape-memory alloy widely used in the manufacture of medical devices 
(Fig. 1). The total length of the device is 50 mm and its outer diameter is 33 mm, designed to cover 
the entire length of the prostatic urethra, from the bladder neck to a point proximal to the external 
urinary sphincter. 
 
Figure 1.  
 Open in figure viewer 
 Download Powerpoint slide 
The Medi-tate TIND in its expanded configuration. (a) Longitudinal view. Note the nitinol struts 
and the anchoring leaflet (*). The total length of the device is 50 mm. The tip of the device is 
covered (soft plastic material) to avoid any bladder injury. (b) Front view. The width of the device 
is 33 mm, the struts are designed to create prostate incisions anteriorly, at the 5 and 7 o'clock 
positions. The anchoring leaflet is marked with*. 
When in its expanded configuration, the struts of the TIND exert radial force outwardly on the 
bladder neck and the prostatic urethra, to push obstructive tissue away from the urinary path. The 
TIND is left in position for 5 days. The device is subsequently removed using a cystoscope sheath 
under visualisation. The device is delivered and removed through a standard 22 F cystoscope (Storz, 
Tuttlingen, Germany) with a 5-mm 30° optic. 
Mechanism of Action 
The radial force exerted by the struts cause ischaemic necrosis of the tissue, leading to bladder neck 
and prostatic urethra incision. The hypothesis is that these incisions ‘reshape’ the prostatic urethra 
and the bladder neck and reduce the urinary flow obstruction caused by the prostatic tissue. 
Surgical Procedure 
1. TIND implantation. The procedure is performed under light i.v. sedation. In addition, as 
antibiotic prophylaxis, a single i.v. dose (500 mg) of levofloxacin is administered. The 
patient is placed in a lithotomy position. The cystoscope is gently inserted in to the urethral 
meatus, and a standard urethro-cystoscopy is performed. The TIND, preloaded on a 
dedicated delivery system, is advanced into the bladder through the cystoscope sheath, and 
deployed inside the bladder. The device is then further manipulated under direct 
visualisation, until the anchoring leaflet slides to its position at 6 o'clock distal to the bladder 
neck and the device is securely positioned within the bladder neck and the prostatic urethra 
(Figs 2 and 3). Finally, the bladder is emptied and the cystoscope is removed. No 
catheterisation is required.  
 
Figure 2.  
o Open in figure viewer 
o Download Powerpoint slide 
(a) The device, preloaded on a dedicated delivery system, is advanced into the bladder 
through the cystoscope sheath, and deployed inside the bladder. (b) The device rotated by 
using the delivery system until the anchoring leaflet (*) reaches the 6 o'clock position. To 
facilitate this step, the bladder is filled with saline solution. 
 
Figure 3.  
o Open in figure viewer 
o Download Powerpoint slide 
Once the device is correctly oriented, it is gently retracted into the prostatic urethra, until the 
anchoring leaflet (*) slides to its position, between the bladder neck and the verumontanum. 
This step of the procedure is performed under direct vision and the surgeon has the tactile 
feedback of the correct positioning of the device. By this way the device is secured within 
the bladder neck and prostatic urethra. —, bladder neck. 
2. TIND removal. At 5 days after placement, the TIND is retrieved in an outpatient setting. 
The patient is placed in a lithotomy position and 20 mL lidocaine gel is applied to the 
urethral meatus. Urethroscopy is performed with a standard 22-F cystoscope, and the TIND 
is identified (Fig. 4), retracted into the cystoscope sheath under visualisation, and then 
removed.  
 Figure 4.  
o Open in figure viewer 
o Download Powerpoint slide 
Endoscopic vision just before TIND removal. Note that anchoring leaflet (*) in its correct 
position, and the incision done by the device anteriorly, at 5 and 7 o'clock positions (—). 
Post-Implantation Care 
Patients were monitored after surgery as per protocols for a standard endoscopic procedure. 
Paracetamol (1 000 mg) was administered i.v. after surgery per local protocol, and then if required 
by the patients. Subjective pain levels were scored using a visual analogue scale (VAS). 
Follow Up Visits 
Patients were visited at 5 days (removal day), 3 and 6 weeks, and 3, 6, and 12 months after the 
implantation. Follow-up visits included uroflowmetry, IPSS and IPSS quality-of-life (QoL) 
assessments. 
To assess patient satisfaction with the surgical intervention, question 32 of the Expanded Prostate 
Cancer Index Composite (EPIC) questionnaire [11, 12] was posed during the follow-up visits: 
‘Overall, how satisfied are you with treatment you received for your prostate disease intervention?’ 
(1: extremely dissatisfied; 2: dissatisfied; 3: uncertain; 4; satisfied; 5: extremely satisfied). 
Adverse events during the follow-up period were recorded. For the purpose of this study, 
complications were defined as ‘early’ when they occurred ≤30 days of surgery and ‘late’ if they 
occurred >30 days after surgery. Early complications were classified according to the Clavien 
system [12]. 
Study Endpoints 
The primary endpoint of the study was to evaluate the feasibility and safety of the procedure; the 
secondary endpoint was to evaluate the functional results of the procedure based on the IPSS and 
uroflowmetry. 
Statistical Analysis 
Data were expressed as means and standard deviations (sds) for continuous variables, and as 
frequencies and proportion or median and interquartile ranges (IQRs) for categorical variables. The 
means of continuous variables were compared by using the Student's t-test after verifying that the 
variables to be analysed were approximately normally distributed. anova was used to compare the 
means of more than two groups, whilst statistical comparisons among different subgroups were 
performed by using the Kruskall–Wallis test for categorical variables. 
Simple and multiple linear regression models were built to identify any independent factors for 
overall complications, improvement of Qmax and decrease in the IPSS at 12 months after surgery. 
Clinical characteristics including age, American Society of Anesthesiologists (ASA) score, body 
mass index (BMI), prostate size, Qmax and the IPSS at baseline, and surgeon were used in the 
regression models. A P < 0.05 was considered to indicate statistical significance. Statsoft (Tulsa, 
OK, USA) Version 8.0 for Windows was used for statistical analysis. 
Results 
Patient Demographics 
In all, 32 patients underwent TIND implantation; their demographic and baseline characteristics are 
summarised in Table 1. 
Table 1. Baseline characteristics of the patients 
Characteristic Value 
1. ECOG, Eastern Cooperative Oncology Group (performance status); 5-ARI, 5α-reductase 
inhibitor. 
Number of patients 32 
Mean (sd) 
Age, years 69.4 (8.2) 
BMI, kg/m
2
 26.1 (4.2) 
PSA level, ng/mL 1.3 (1.2) 
Prostate volume, mL 29.5 (7.4) 
Qmax, mL/s 7.6 (2.2) 
Preoperative haemoglobin levels, g/dL 14.0 (1.2) 
Median (IQR) 
ASA score 2 (2–3) 
ECOG score 0 (0–1) 
Preoperative IPSS 19 (14–23) 
Preoperative IPSS QoL index 3 (3–4) 
Charlson comorbidity index 1 (0–2) 
N (%) 
Characteristic Value 
Patients with bladder catheter before the intervention 0 
α-blocker therapy 32 (100) 
α-blocker + 5-ARI therapy (%) 15 (46) 
Perioperative Results 
All patients were treated with light sedation, and all the implantations were successful. No 
intraoperative complications were recorded. The mean (sd) operative time, from introduction of the 
TIND system until withdrawal of the delivery system, was 5.8 (2.5) min. 
The median (IQR) VAS score at 6 h after the procedure was 2 (2–4), while the median paracetamol 
use during this period was one 1 000 mg vial per patient. The median (IQR) duration of the 
postoperative stay was 1 (1–2) days. From the 20th procedure, patients were discharged on the same 
day as the surgery. None of the patients was readmitted before device removal. All but one of the 
devices was removed 5 days after implantation, in an outpatient setting. The mean (sd) operative 
time was 2 (1) min, and all procedures were uneventful. 
Complications 
Overall, four patients (12.5%) presented complications that are summarised in Table 2. One patient 
(3.1%) reported urinary incontinence 1 day after surgery, so the device was immediately removed. 
During the cystoscopy, the distal portion of the wires was identified distal to the sphincter, 
suggesting displacement of the device. After TIND removal, the patient reported no urine leakage. 
One patient (3.1%) had urinary retention the same day of the implantation. In this case, the bladder 
was voided by using a small (10 F) Tieman catheter, which was immediately removed. Thereafter, 
the patient was able to urinate spontaneously. Two patients (6.2%) developed infections. In the first 
case, a UTI was diagnosed 2 weeks after the implantation and was successfully treated by antibiotic 
therapy. The second patient (affected with type II diabetes) presented fever (38 °C) with urinary 
symptoms, atrial fibrillation and uncontrolled glucose levels (>400 mg/dL) 4 weeks after 
implantation. He was readmitted, blood tests and TRUS were performed with a diagnosis of a 2-cm 
prostatic abscess. The patient was successfully treated with medical therapy, with no sequelae after 
discharge (Table 2). No late complications were recorded. Furthermore, no patients required 
adjunctive surgical treatments during the follow-up period. When comparing the subgroup of 
patients who had postoperative complications (four patients) with the subgroup of patients who did 
not (28), there were no differences in age, BMI, preoperative PSA levels, IPSS, co-morbidities, 
ASA score, prostate volume or operative time. Multiple regression analysis failed to identify any 
independent prognostic factors for complications. 
Table 2. Complications after TIND implantation 
Patient 
ID 
Demographic 
data 
Complication Grade* Early/late Management Sequelae 
1. AF, atrial fibrillation; *According to Clavien system. 
ITA 
0101 
Age 69 years 
BMI 
18.7 kg/m
2
 
Prostatic abscess 
(sepsis, AF, 
uncontrolled 
glycaemia) 
II Early 
Readmission 
1. Ertapenem 
(1 g/day i.v.) for 
9 days, amikacin 
None 
Patient 
ID 
Demographic 
data 
Complication Grade* Early/late Management Sequelae 
Charlson score 
3 
ASA score 3 
PSA level 
0.5 ng/mL 
Prostate size 
25 mL 
for 7 days 
2. Amiodarone 
(300 mg, i.v.) for 
1 day 
3. Insulin (s.c) for 
10 days, then usual 
oral therapy 
Postoperative stay of 
readmission: 10 days 
ITA0109 
Age 78 years 
BMI 
21.9 kg/m
2
 
Charlson score 
0 
ASA score 3 
PSA level 
0.47 ng/mL 
Prostate size 
27 mL 
Urinary retention 
(same day of 
implantation) 
II Early 
Catheter positioning 
(immediately removed) 
None 
ITA0119 
Age 71 years 
BMI 
27.6 kg/m
2
 
Charlson score 
0 
ASA score 2 
PSA level 
0.4 ng/mL 
Prostate size 
34 mL 
Transient 
incontinence due 
to device 
displacement 
III Early 
Early (postoperative day 
1) removal of device 
None 
ITA0123 
Age 71 years 
BMI 
30.1 kg/m
2
 
Charlson score 
4 
UTI II Early 
Levofloxacin 500 mg/day 
orally for 14 days 
None 
Patient 
ID 
Demographic 
data 
Complication Grade* Early/late Management Sequelae 
ASA score 3 
PSA level 
1.2 ng/mL 
Prostate size 
39 mL 
Functional Results 
Qmax values, the IPSS and IPSS QoL index results measured at the baseline and at scheduled time 
points during the follow-up period are reported in Figs 5 and 6. Figures 7 and 8 show the percentage 
changes in Qmax and the IPSS at the different time points with respect to baseline. There were no 
differences in the IPSS and IPSS QoL index among the different time points during the follow-up, 
on the contrary, there were statistically significant variations in Qmax during the follow-up (Table 3). 
All patients discontinued medical therapy at 3 months after surgery. Multiple regression analysis 
did not identify any independent prognostic factor predictive of higher improvement of the IPSS 
and Qmax. At 12 months after surgery (last follow-up visit), no patients required medical therapy or 
surgical procedures for BPH. For the EPIC score (Fig. 6 and Table 3) at 12 months after surgery, 26 
patients (82%) were ‘satisfied’ or ‘extremely satisfied’ with the intervention, five (15%) patients 
were uncertain about their satisfaction and only one (3%) patient was ‘dissatisfied’. 
Table 3. Functional results and overall satisfaction of patients with TIND procedures evaluated 
during the follow-up 
  3 weeks 6 weeks 3 months 6 months 12 months P  
1. a  
‘Overall, how satisfied are you with treatment you received for your prostate disease 
intervention?’ (1: extremely dissatisfied; 2: dissatisfied; 3: uncertain; 4; satisfied; 5: 
extremely satisfied). 
Mean (sd) Qmax, mL/s 10.0 (4.4) 12.5 (4.1) 11.7 (4.7) 11.4 (4.2) 11.9 (4.7) <0.01 
Median (IQR) 
IPSS 10 (8–11) 8 (7–10) 8 (6–10) 9 (7–12) 9 (7–13) 0.18 
IPSS QoL index 2 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 0.45 
EPIC index question 
32a 
5 (4–5) 5 (4–5) 5 (4–5) 5 (4–5) 5 (4–5) 1 
 Figure 5.  
 Open in figure viewer 
 Download Powerpoint slide 
Qmax evaluated pre- and postoperatively. The differences between the pre- and postoperative values 
at every time point were statistical significant. pre., preoperative; w., weeks; mo., months. 
 
Figure 6.  
 Open in figure viewer 
 Download Powerpoint slide 
The IPSS, IPSS QoL score and EPIC score evaluated pre- and postoperatively. The differences 
between the pre- and postoperative values at every time point were statistical significant for all the 
considered variables. p.o., postoperatively. 
 Figure 7.  
 Open in figure viewer 
 Download Powerpoint slide 
Changes in Qmax at the different time points with respect to baseline values. IQmax, increase in 
Qmax; w., weeks; mo., months. 
 
Figure 8.  
 Open in figure viewer 
 Download Powerpoint slide 
Changes in the IPSS at the different time points with respect to baseline values. DIPSS, decrease in 
IPSS; w., weeks; mo., months. 
Discussion 
Many men with LUTS due to BPH are dissatisfied with current medical treatment options but do 
not accept TURP or more recent laser-based therapies as an option, mainly due to subsequent sexual 
dysfunction, perioperative urinary urgency/frequency symptoms or risks of complications. In 
addition, some Authors have reported that LUTS have a lower impact on QoL than sexual 
dysfunction or incontinence [1, 13-15]. To reduce the invasiveness of TURP, many minimally 
invasive surgical options have been proposed during recent decades (Table 4) [16-24]. 
Table 4. Results of minimally invasive techniques for the treatment of LUTS due to BPH 
References Procedure 
Follow-
up, 
weeks 
Patients, 
n 
Estimated 
change in 
IPSS, % 
Estimated 
change in 
Qmax, % 
Main complications 
1. a  
Three study arms comparing transurethral, transrectal and transperineal injections; NA, not 
available. 
Hoffman 
et al. [18] 
TUMT 52 322 −65 70 NA 
Trock et al. 
[21] 
TUMT 208 541 −42.7 35 NA 
Guazzoni 
et al. [16] 
Urolume 18 91 −66.6 83.8 
Long-term complications 
38% 
Gesenberg 
and 
Sintermann 
[22] 
Memotherm 104 123 −74.5 125.6 
Early postoperative  
Haematuria 51.2%; 
dislocation 8.9%  
3–12 months 
postoperative  
UTI 45.5%; urothelial 
hyperplasia 27.6%, 
dislocation 1.6%, 
explantation 4.1%, 
ureteric stricture 10.6%, 
stone formation 3.2% 
Perry et al. 
[23] 
Memokath 336 211 −59.6 NA 
Migration 13%; urinary 
retention 10%, 
incontinence 6%; UTI 
6%, stone formation 2% 
Grise et al. 
[19] 
TEAP 52 115 −50 35 
Urinary retention 17%, 
haematuria 16%, UTI 
8%, incontinence 4%, 
erectile dysfunction 3%, 
ejaculatory dysfunction 
1% 
Plante et al. 
[20] 
TEAP 24 79 −47 to −55a 37–94a 
Irritative voiding 
symptoms 40.3%, urinary 
References Procedure 
Follow-
up, 
weeks 
Patients, 
n 
Estimated 
change in 
IPSS, % 
Estimated 
change in 
Qmax, % 
Main complications 
retention 22.1%, UTI 
10.1%; erectile 
dysfunction 3.7%, 
ejaculatory dysfunction 
3.7% 
Hill et al. 
[17] 
TUNA 52 56 −51.2 NA 
Erectile dysfunction 3%, 
urinary incontinence 2%; 
re-intervention 13.8% 
Zlotta et al. 
[24] 
TUNA 52 131 −58.3 40.6 NA 
The ‘prostatic’ stent was primarily designed as an alternative to an indwelling catheter in patients 
unfit for surgery but it has also been indicated as a primary treatment option in patients without 
significant co-morbidities [16, 25]. Because of the side-effects and the high migration rate, prostatic 
stents have a limited role in BPH treatment [5]. Heating therapies with microwaves and 
radiofrequencies (TUMT and TUNA) may have fewer complications than TURP [17, 18]. 
However, it is known they might have unpredictable results and require up to 2 months of worsened 
symptoms before a significant improvement of Qmax and the IPSS [5, 26]. 
The minimally invasive TEAP option is scarcely covered in the Literature and its mechanism of 
action has not been well investigated. In addition, the technique has not been standardised and 
finally, severe adverse events have been reported [19]. For these reasons, TEAP is still considered 
experimental and should be used only in trials [5, 20]. More recently, the PUL procedure has been 
proposed as a novel, minimally invasive technique to improve LUTS due to BPH [9, 10]. In the 
PUL procedure, the lateral lobes of the prostate are displaced by small suture-based implants 
towards the capsule with the aim of expanding the urethral lumen [9, 10, 27]. In the first clinical 
experience with 19 patients, at 1 year after PUL the mean IPSS decreased by 39% compared with 
the baseline value [9]. However, non-significant increases in Qmax at the different time points were 
reported. In a recent multinational experience, the IPSS, IPSS QoL score and Qmax significantly 
improved 1 year after the procedure, yet 6.5% of the patients progressed to TURP within 1 year 
[10]. 
TIND was developed in an effort to create an efficient and minimally invasive technique for 
treating the symptoms of urinary outflow obstruction secondary to BPH. In the present study, we 
report the first clinical experience with TIND and show that the implantation of this device is 
feasible and safe in the treatment of BPH-related symptoms. All the procedures were successfully 
completed, performed under light sedation, and required only a few minutes to perform. Neither 
intraoperative complications nor technical difficulties were recorded. From a technical point of 
view, the procedure was simple and did not require any special equipment. The key point is the 
correct placement of the device; after filling of the bladder with saline solution, the device must be 
delivered into the bladder and rotated until the anchoring leaflet is placed at the 6 o'clock position at 
the bladder neck. Once this orientation is correct, the device is gently retracted until the anchoring 
leaflet slides distal to the bladder neck. Unlike other minimally invasive procedures, the surgeon has 
direct visualisation of the device throughout the procedure. Moreover, at his discretion, the surgeon 
can easily relocate and even withdraw the device even after it has been deployed. During the 
postoperative period, paracetamol (1 000 mg, i.v.) was administered to all patients, per local 
protocol, and no patients required adjunctive analgesic drugs, suggesting that overall the procedure 
was well tolerated. All but one patient was able to void the same day of surgery, with no need of 
postoperative catheterisation. This is one of the most positive aspects of the procedure. The duration 
of hospital stay was longer for the first patients, who were more strictly monitored during the 
postoperative period, as it is standard when implementing new techniques. However, after the initial 
encouraging results, all patients were discharged on the same day of the surgery. 
Theoretically, one of the major concerns of this procedure was the tolerability of the device once 
implanted. After the discharge and before the TIND removal (at day 5), we recorded neither 
unplanned visits nor readmissions, suggesting that the device was well tolerated by all the patients. 
Removal of the device was performed without any complications in all cases. All patients were able 
to void immediately after device removal, confirming the feasibility of this manoeuvre in an 
ambulatory setting. 
Overall, there were four ‘early’ complications (Table 2). Of note, one patient reported urinary 
incontinence due to device displacement, but after removal, the patient was completely continent. In 
one patient, prostatic abscess complicated by sepsis, atrial fibrillation and uncontrolled glycaemia 
was recorded 4 weeks after implantation. The patient was readmitted and pharmacologically treated 
with no sequelae after discharge. Regression models failed to identify any independent prognostic 
factors for complications, despite the fact that both infections were recorded in patients with ASA 3 
and a Charlson comorbidity index higher than the median value. After implantation, no 
complications occurred in the studied population during the first 30 days, demonstrating the safety 
of the procedure. For functional results, significant improvements in the postoperative IPSS and 
Qmax compared with baseline were recorded. Notably, this improvement was recorded early, within 
3 weeks of the procedure, presenting an important positive aspect of this procedure, as the vast 
majority of other minimally invasive techniques can require several weeks before improvement [5, 
19]. Moreover, the IPSS remained stable during the entire follow-up period. Slight but statistically 
significant changes were observed in Qmax measured at the different time points during the follow-
up (Table 3), even if probably not clinically relevant. After 1 year, the mean improvement of the 
IPSS and Qmax was 45% and 67%, respectively. Notably, all patients discontinued medical therapy 
3 months after surgery. These results are at least comparable, if not superior, to those of other 
minimally invasive procedures, even the most novel ones [7, 28]. The QoL scores followed the 
same trend as the IPSS, with patients reporting a significant improvement in QoL, which remained 
stable at the different follow-up time points throughout the study (Table 3). These data suggested 
that TIND implantation positively affected the QoL of the patients, a key factor when assessing a 
new surgical strategy for BPH treatment. The results of EPIC question 32 further confirmed that the 
procedure was well accepted by the patients. Finally, no patients required more invasive treatments 
(i.e., TURP) during the follow-up period, further demonstrating the efficacy (at least measured in a 
short follow-up period) of the procedure. We consider this result noteworthy when compared with 
other techniques [10, 29, 30]. 
The present study was not devoid of limitations. Firstly, the sample size was small. Secondly, the 
duration of follow-up was somewhat short. Nevertheless, one must note that the main endpoint of 
our present study was to demonstrate the feasibility and safety of the procedure, and we think that 
the presented data are sufficient in demonstrating these points. Thirdly, prostate size was small and 
treatment results for larger prostates are lacking. 
Notwithstanding the abovementioned limitations, we can conclude that TIND implantation is a 
feasible and safe minimally invasive option for the treatment of BPH-related LUTS, as evidenced 
by the excellent perioperative results and the low complication rate. The procedure is simple, fast (a 
few minutes) and does not require any special equipment. The functional results are encouraging 
and the treatment significantly improved the patient's QoL. Further studies are required to assess the 
long-term durability of TIND results and to better define the indications of such a procedure. 
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